Ovarian function during use of a levonorgestrel-releasing IUD. 1990

I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
Department of Obstetrics and Gynecology, University of Uppsala, Sweden.

Ovarian function was studied for two complete menstrual cycles in 9 regularly menstruating women and for 8 weeks in three amenorrhoeic women who had used levonorgestrel-releasing IUDs (LNG-IUD) for more than four years. Nine patients using copper IUDs (Nova-T) were studied for two complete menstrual cycles as controls. According to progesterone levels, 15/17 cycles in women using LNG-IUDs were ovulatory, whereas only 8/17 cycles showed normal follicular growth and rupture as judged by ultrasound. In ovulatory cycles, the peak progesterone levels were lower than in the controls. The preovulatory estradiol and LH peak levels were also lower than in control subjects. SHBG levels were lower in LNG-IUD users than in copper IUD users. It is concluded that, although the dose of levonorgestrel released from the IUD is very low, it probably exerts an effect on the gonadotrophin secretion, which disturbs follicular development in many of the women studied, which in addition to the local effect on the endometrium, contributes to its high contraceptive efficacy.

UI MeSH Term Description Entries
D007435 Intrauterine Devices, Copper Intrauterine contraceptive devices that depend on the release of metallic copper. Copper Intrauterine Devices,Copper-Releasing IUDs,IUD, Copper Releasing,Copper Intrauterine Device,Copper Releasing IUD,Copper-Releasing IUD,Device, Copper Intrauterine,Devices, Copper Intrauterine,IUD, Copper-Releasing,IUDs, Copper-Releasing,Intrauterine Device, Copper
D007436 Intrauterine Devices, Medicated Intrauterine devices that release contraceptive agents. Hormone-Releasing IUDs,IUD, Hormone Releasing,Intrauterine Devices, Hormone-Releasing,Intrauterine Devices, Progesterone-Releasing,Medicated Intrauterine Devices,Device, Hormone-Releasing Intrauterine,Device, Medicated Intrauterine,Device, Progesterone-Releasing Intrauterine,Devices, Hormone-Releasing Intrauterine,Devices, Medicated Intrauterine,Devices, Progesterone-Releasing Intrauterine,Hormone Releasing IUD,Hormone-Releasing IUD,Hormone-Releasing Intrauterine Device,Hormone-Releasing Intrauterine Devices,IUD, Hormone-Releasing,IUDs, Hormone-Releasing,Intrauterine Device, Hormone-Releasing,Intrauterine Device, Medicated,Intrauterine Device, Progesterone-Releasing,Intrauterine Devices, Hormone Releasing,Intrauterine Devices, Progesterone Releasing,Medicated Intrauterine Device,Progesterone-Releasing Intrauterine Device,Progesterone-Releasing Intrauterine Devices
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D008297 Male Males
D009644 Norgestrel A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis. 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-,DL-Norgestrel,Neogest,Ovrette,Postinor,Wy-3707,DL Norgestrel,Wy 3707,Wy3707
D010053 Ovary The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE. Ovaries
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D002582 Cervix Mucus A slightly alkaline secretion of the endocervical glands. The consistency and amount are dependent on the physiological hormone changes in the menstrual cycle. It contains the glycoprotein mucin, amino acids, sugar, enzymes, and electrolytes, with a water content up to 90%. The mucus is a useful protection against the ascent of bacteria and sperm into the uterus. (From Dictionary of Obstetrics and Gynecology, 1988) Fern Test,Palm-Leaf Reaction,Cervical Mucus,Fern Tests,Mucus, Cervical,Mucus, Cervix,Palm Leaf Reaction,Palm-Leaf Reactions,Reaction, Palm-Leaf,Reactions, Palm-Leaf,Test, Fern,Tests, Fern
D003271 Contraceptive Agents, Female Chemical substances or agents with contraceptive activity in females. Use for female contraceptive agents in general or for which there is no specific heading. Contraceptives, Female,Agents, Female Contraceptive,Female Contraceptive Agents,Female Contraceptives
D004717 Endometrium The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo. Endometria

Related Publications

I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
June 1995, Advances in contraception : the official journal of the Society for the Advancement of Contraception,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
February 1989, Contraception,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
July 2015, The Medical letter on drugs and therapeutics,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
September 2001, The Israel Medical Association journal : IMAJ,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
December 1982, Clinical endocrinology,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
September 1982, Contraception,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
July 1999, Harefuah,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
April 1977, Contraception,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
March 2013, The Medical letter on drugs and therapeutics,
I Barbosa, and O Bakos, and S E Olsson, and V Odlind, and E D Johansson
January 1984, Contraception,
Copied contents to your clipboard!